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ABSTRACT 
Background and aims: Carotid artery plaque is an established marker of subclinical atherosclerosis and 
common patho-mechanisms with coronary artery disease (CAD) are hypothesized.  We aimed to 
identify genetic variants associated with carotid plaque and examine the potential shared genetic basis 
with CAD.  
Methods: After investigating the reliability of plaque detection, we performed a genome-wide meta-
association study in two independent cohorts (LIFE-Adult, n=4,037 and LIFE-Heart, n=3,152) for carotid 
plaque score (PS), defined as the sum of the plaque load of common carotid artery and carotid bulb. 
Further, we analyzed whether previously reported CAD and stroke loci were also associated with PS. 
Results: We identified two loci with genome-wide significance for PS. One locus is the known CAD-
locus at chromosome 9p21 (lead SNP rs9644862, p=8.73x10-12). We also describe a novel locus at on 
chromosome 10q24 within the SFXN2 gene as the most probable candidate (lead SNP rs2902548, 
p=1.97x10-8). In addition, 17 out of 58 known CAD loci and six of 17 known stroke loci were associated 
with PS at a nominal level of significance.  
Conclusion: We showed that PS is a reliable trait to analyze genetics of atherosclerosis. Two new loci 
of genome-wide significant association with PS were found. The observed non-random overlap of CAD 
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Introduction 
Coronary artery disease (CAD) is a complex disease determined by numerous environmental and 
genetic factors [1]. Over the last several years, genome-wide association analyses have led to the 
identification of several genetic loci associated with CAD and myocardial infarction (MI).  The most 
recent meta-analysis of Nikpay et al. [2] included about 185,000 cases and controls adding further 
evidence and resulting in a total of 58 loci considered as well-established.  However, these studies 
typically comprise a highly heterogeneous mixture of assessments and information to determine 
disease status, e.g. anamnestic data, clinical records, coronary angiography or acute myocardial 
infarction.  Therefore, to gain a better understanding of the underlying genetic patho-mechanisms, it 
appears worthwhile to study whether these loci are also related to other manifestations of 
atherosclerosis.  
Carotid intima-media thickness (cIMT) and carotid artery plaque are promising assessment for this 
purpose. Intima-media thickness was reported to be predictive for cardiovascular events [3, 4]. 
However, the importance of cIMT in comparison to established risk scores  such as the Framingham 
Risk Score was challenged by others [5]. Studies have also shown an association of carotid parameters 
with prevalent CAD with the predictive value of carotid plaque outperforming that of intima-media 
thickness [6, 7]. In a large cohort of patients with suspected CAD receiving coronary angiography (LIFE-
Heart), we have recently also found a strong correlation of plaque status in the carotid artery and 
lesions in coronary vessels with an odds ratio (OR) >3.7 [8]. Again, carotid plaque showed a 
considerably stronger association with CAD than intima-media thickness proposing carotid plaque as 
a non-invasively assessable marker of coronary lesions. Based on these findings, we hypothesized that 
there may be a shared genetic basis for carotid artery plaques and CAD.  
Here, we performed a large genome-wide association analysis of carotid plaques in two independent 
cohorts collected in the LIFE Research Center of Civilization diseases. While previous studies focused 
on plaque prevalence [9, 10] or plaque size [11], we used the number of carotid plaques as primary 
end point.  
In a secondary analysis, we investigated whether there is an enrichment of plaque associations for CAD 
risk loci to detect possible genetic similarities and differences of these atherosclerotic phenotypes.   
In analogy, we analyzed loci associated with ischemic stroke (IS) as found by Dichgans et al. [12] and 
Pulit et al. [13].  Both authors defined subtypes of stroke using the Trial of Org 10 172 in Acute Stroke 
Treatment (TOAST) classification system [14]. One subtype is large artery stroke (LAS), which requires 
a stenosis of greater than 50% of the extracranial internal carotid artery (ICA). We analyzed this sub-
phenotype separately since plaque assessment was available in proximal ICA in our cohorts.   
 
Materials and methods 
Cohort description  
LIFE-Adult 
LIFE-Adult is a population-based cohort of 10,000 adult inhabitants of the city of Leipzig, Germany.  
Participants are well characterized regarding life-style and environmental risk factors and clinical and 
subclinical signs of diseases such as cardiovascular diseases, type 2 diabetes or cognitive impairment. 
Detailed description of the cohort can be found elsewhere [15]. CAD status in LIFE-Adult was 
determined by the following anamnestic criteria:  MI, stent implementation during a coronary 
angiography or diagnosed CAD.  
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LIFE-Heart 
LIFE-Heart is a cohort of patients with suspected and confirmed stable coronary artery disease or 
myocardial infarction as first manifestation of CAD. All patients underwent coronary angiography and 
vascular phenotyping at the Heart Center of the University of Leipzig. Details of the study can be found 
elsewhere [16]. A total of about 7,000 patients were recruited so far. CAD status is defined by the 
presence of at least one coronary lesion with more than 50% luminal reduction.   
Both, LIFE-Adult and LIFE-Heart, meet the ethical standards of the Declaration of Helsinki. They have 
been approved by the Ethics Committee of the Medical Faculty of the University Leipzig, Germany 
(LIFE-Adult: Reg. No 263-2009-14122009, LIFE-Heart: Reg. No 276-2005). LIFE-Heart is registered at 
ClinicalTrials.gov (NCT00497887). Written informed consent including agreement with genetic 
analyses was obtained from all participants.  
A description of basic parameters of LIFE-Adult in comparison with those of LIFE-Adult is shown in table 
1.  
   
Carotid ultra-sound and plaque assessment 
For both cohorts, carotid ultrasound was performed using the same standard operating procedures. 
Subjects with cervical spine disorder, wounds at the scanning area and patients with acute myocardial 
infarction in LIFE-Heart were excluded from carotid ultrasound. 
Eligible patients were scanned at both sides of four anatomical regions: common carotid artery (CCA), 
carotid bulb (Bulb), proximal parts of internal carotid artery (ICA) and external carotid artery (ECA) 
respectively. High-resolution B-mode ultrasound images of carotid vessels were acquired using the GE 
Vivid ultrasound platform with a 12.0-MHz linear-array transducer (GE-Healthcare). For the 
assessments, subjects were in supine position.   
Carotid artery plaque was defined according to the American Society of Echocardiography Intima-
Media Thickness Task Force [17]. In detail, a lesion was counted as plaque if echogenic thickening of 
intimal reflection that extends into the arterial lumen at least 0.5 mm or 50 % of the surrounding 
intima-media thickness or thickness of intima and media >1.5 mm. Plaque presence was documented 
as ‘present’ or ‘absent’ or ‘missing’ if the quality of the image was insufficient. Details can be found 
elsewhere [8].  
Prior to LIFE recruitment, we performed a feasibility study of N=47 volunteers receiving repeated 
plaque readings by six different investigators. We observed a high intra- (κ=0.93 for the overall 
agreement) and inter-rater reliability (κ=0.88 for the overall agreement with the consented plaque 
assessment, data not shown). Based on the single plaque assessments, we defined the plaque score 
(PS) as follows. PS is the sum of the plaque assessments at CCA and Bulb on both sides. Thus PS takes 
values from 0 to 4. Single missing values are counted as zeros for this purpose. If there is more than 
one missing value, the score is set to missing.  
A possible alternative to this phenotype definition is a more comprehensive evaluation of all four 
scanned carotid areas on both side (PS8, with values in between 0 and 8). Plaque scores PS and PS8 
were highly correlated (r=0.91 for both LIFE-Heart and LIFE-Adult). However, as ICA and ECA were more 
difficult to scan, there is a substantially higher percentage of missingness for PS8 compared to PS. 
Therefore, we decided to use PS as our primary endpoint. However, for consistency we verified our 
main results using this alternative plaque phenotype. For the purpose of comparisons with established 
stroke loci, we analyzed the four anatomical regions separately considering scores of corresponding 
plaque burden which take values 0, 1 and 2.  
Carotid ultra-sound was available for 9,858 participants of LIFE-Adult and 3,501 patients of LIFE-Heart. 
Distributions of PS in both cohorts are presented in table 1.  
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Genotyping 
LIFE-Adult 
A total of 5,101 randomly selected individuals were genotyped using the genome-wide SNP array 
Affymetrix Axiom CEU1. Genotype calling was performed following the best practice steps 
recommended by Affymetrix [18]. The software “Affymetrix Power Tools” (APT, version 1.17.0) was 
used with the latest library “Axiom GenomeWide CEU 1 Array Plate, Analysis Files, release 6”.  
We filtered 73 samples failing the dishQC criteria (dishQC ≥ 0.82) and sample call rate criteria (SCR ≥ 
97%) in the initial calling round. Genotypes of 587,352 SNPs were determined in the final calling round. 
Sex-mismatches were filtered. Additionally, the intensities of gonosomal SNPs were plotted to check 
for further abnormalities as proposed by Laurie et al. [19]. Cryptic relatedness was assessed according 
to Wang [20]. Duplicates were removed keeping the sample with the higher quality. Principal 
component analysis (PCA) as suggested by Patterson et al. [21] was performed using PLINK [22, 23] 
(version 1.9). Ethnical outliers (>6 SD of first ten PCs) were removed, which resulted in a final set of 
4,985 unrelated high quality samples for autosomal analyses and 4,978 for gonosomal analyses.  
Autosomal SNPs were filtered for call rate (CR < 97%), the cluster plot quality criteria as suggested by 
Affymetrix (i.e. Fisher’s Linear Discriminant, heterozygous strength offset, homozygote ratio offset), p 
value of exact test for Hardy-Weinberg equilibrium (HWE<10-6), monomorphic SNPs and p value of 
plate association (<10-7, i.e. test for dependency of allele frequency to plate). A total of 532,875 SNPs 
fulfilled all quality criteria.  
For X-chromosomal SNPs, filter criteria proposed by Konig et al. [24] were applied (p value of exact test 
for HWE for women <10-4, CR<98%, and minor allele frequency (MAF)<1% after setting all 
heterozygous calls in male samples on missing). This resulted in 13,554 X-chromosomal SNPs eligible 
for analysis. 
Finally, all 4,985 samples were imputed, using 1000 Genomes Phase 1, Version 3 [25] (2012) as 
reference, SHAPEIT [26] (version v2.r790) for phasing, and IMPUTE2 [27] (version 2.3.2) for imputation. 
Imputation for X-chromosomal SNPs was performed using the same reference panel and software, but 
with the subset samples eligible for X-chromosomal analysis as mentioned above.  
LIFE-Heart 
LIFE-Heart samples were genotyped with either Affymetrix Axiom CEU1 or Affymetrix Axiom CADLIFE. 
The latter is an array containing Axiom CEU as genome-wide backbone and an additional custom 
content of about 62,500 SNPs from CAD loci.  Genotype calling relied on Affymetrix Power Tools (APT, 
version 1.17.0 for Axiom-CADLIFE, version 1.16.1 for Axiom-CEU) with their latest libraries (Axiom 
CADLIFE1, release 3 respectively Axiom GenomeWide CEU 1 Array Plate, Analysis Files, release 6). 
Genotype calling and SNP filtering was performed separately for the two array products. For sample 
filtering, high quality SNPs in the intersection of both arrays were used. The same steps of sample and 
SNP filtering were performed as in LIFE-Adult. In summary, 5,700 samples and 504,593 SNPs fulfilled 
all quality criteria for autosomal analyses. For X-chromosomal analyses, additional 12 samples were 
removed and a total of 12,715 SNPs fulfilled the specified quality criteria.  
Imputation was performed using the same reference, software and software settings as in LIFE-Adult. 
The intersection of SNPs of Affymetrix Axiom CEU1 and Affymetrix Axiom CADLIFE was used for this 
purpose. 
Statistical Analysis 
PS was available for 4,037 successfully genotyped samples of LIFE-Adult and 3,152 samples of LIFE-
Heart sub cohort of patients initially admitted for suspected CAD. Separate genome-wide analysis was 
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performed for each cohort first. The analysis was executed with PLINK [22, 23] (version 1.9) using the 
additive frequentist model and expected genotype counts, adjusting for sex and age (LIFE-Heart: 
beta=0.54 for males and beta=0.03/year for age; LIFE-Adult: beta=0.44 for males and beta=0.03/year 
for age; all betas significant with p<0.001). X-chromosomal SNPs were analyzed assuming total X 
inactivation. PS was treated as continuous since the difference of test statistics compared to those of 
proportional odds logistic regression appeared to be small (correlation of test statistics r>0.99 for both 
cohorts).    
SNPs not in the intersection of the studies, with MAF<1% or info-score<0.3 in one of the studies were 
initially filtered, leaving 9,846,747 million SNPs for further analysis. A fixed effect model (FEM) meta-
analysis was then performed for all remaining SNPs using the package meta of R. A genome-wide 
significance threshold of 5.0x10-8 was applied. The study has a power of 80% respectively 90% to detect 
variants explaining 0.5% respectively 0.6% of variance. 
To determine independent variants, we applied a priority pruning using linkage disequilibrium data 
from 1000 Genomes Phase 1, Version 3 (2012), restricted to individuals with European ancestry. 
Variants which are in linkage disequilibrium (LD) with an association of higher significance were 
removed if r²≥0.5.  
We performed a comprehensive annotation of our top-SNPs using a number of bioinformatic 
resources: We reported known genome-wide association study (GWAS) hits, using the GWAS 
catalogue [28], if in linkage disequilibrium (r2>0.2) with one of our top-hits. Analogously, we add 
expression quantitative trait loci (eQTL) data as explained in Kirsten et al. [29]. Pathway enrichment 
was performed for each SNP by including physically nearby genes, all within 50 kb distance and up to 
four within 250 kb distance, and eQTLs in LD (r2>0.2) with the variant. Pathways were retrieved from 
KEGG, GO, DOSE [30], and reactome. We also calculated deleteriousness scores according to Kircher 
et al. [31].  
In addition, we tried to replicate five SNPs which were reported to be associated with carotid plaque 
prevalence (Bis et al. [9]) with our score. To analyze a possible shared genetic background of carotid 
plaques and CAD, we analyzed 58 loci for which associations with CAD were described in the literature 
[2]. Of the 58 top-SNPs of these loci, ten were directly genotyped in both of our cohorts. All other SNPs 
were successfully imputed. To analyze enrichment of significant associations with concordant direction 
of effects, we compared this percentage with 2.5% expected by chance.  
We also analyzed SNPs in LD (r2>0.5) with the reported CAD SNPs and determined the SNP with 
strongest plaque association per locus. This results in a higher number of CAD loci showing nominal 
significance for plaque. To compare this number with the one expected by chance, we performed 
permutation analysis. 10,000 permutations of phenotypes (PS, sex, age) and genotypes were analyzed. 
An empirical p value was calculated assuming a Poisson distribution of the number of significant loci. 
Additionally, we calculated a genetic risk score (GRS) of CAD using the beta estimates of Nikpay et al. 
[2] in order to analyze its association with our trait.  
Similarly, we analyzed loci  associated with cIMT [9, 32], ischemic stroke (IS) [12, 13] and large artery 
stroke (LAS) [12].   
 
Results 
Genome-wide significant hits for plaque score 
Meta-analysis of 9,576,485 SNPs in the LIFE-Adult and LIFE-Heart studies showed no signs of inflation 
(λ =1.004). QQ-Plot and Manhattan plot can be found in figure 1. We identified two loci at chromosome 
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9p21 and 10q24 with genome-wide significant hits (p<5x10-8) in our study (Table 2, further results are 
summarized in supplementary table 1).   
The strongest association with PS was observed for SNP rs9644862, located at 9p21 in the sequence 
of CDKN2B-AS1 (also known as ANRIL), i.e. the best established common locus of CAD association. This 
SNP showed robust associations with similar effect sizes in both cohorts (LIFE-Heart: beta=0.174, 
p=3.36x10-7, LIFE-Adult: beta=0.111, p=1.87x10-6, FEM: beta=0.131, p=8.73x10-12). No interactions with 
sex were observed (LIFE-Heart: p=0.53, LIFE-Adult: p=0.47). Our lead SNP rs9644862 is in linkage 
disequilibrium (r²=0.75) with rs2891168, which was reported as top-SNP in the most recent GWAS of 
CAD [2] (see also supplementary table 2). For our top-SNP no direct eQTLs were observed. But it is in 
strong LD (r2=0.75) with rs4977574 which is an expression quantitative trait nucleotide (eQTN) of 
CDKN2B [33].  Other, partly stronger eQTLs but in weaker LD with the top-hit are presented in 
supplementary table 3.  
After pruning with r²=0.5, another SNP at the 9p21 locus (rs7853090) also showed genome-wide 
significance. This SNP is in weak LD with the top-SNP (r²=0.28). A regional association plot of the locus 
is shown in figure 2A. 
Besides the 9p21 locus, we identified a second locus at 10q24 reaching genome-wide significance (lead 
SNP rs2902548; FEM: beta=-0.141, p=1.97x10-8, Table 2). The lead SNP is located in the intron of SFXN2. 
Other nearby genes are ARL3 (13 kb), WPL1P (16 kb) and TRIM8 (69 kb, figure 2B). SNP rs2902548 is 
an eQTN for several cis-regulated genes including those mentioned above (supplementary table 3). 
The strongest eQTL (p=8.6x10-26, The GTEx Consortium [34]) was observed  for SFXN2 in esophagus 
tissue, and a weaker one in left ventricular heart tissue (p=6.1x10-10, The GTEx Consortium [34]).  There 
is also an eQTL-SNP in LD with rs2902548 at ARL3 in tissue of the artery aorta (p=1.5x10-5, r²=0.56, The 
GTEx Consortium [34]). Restricted to blood tissue, the strongest eQTL was found for SFXN2, C10orf32, 
and ARL3 (p=3.6x10-15, p=1.8x10-11, and p=4.2x10-10, respectively, Westra et al. [35]).  SNP rs2902548 
is also in weak LD (r²<0.3) with several SNPs previously reported for cardiovascular risk factors such as 
BMI and hypertension (supplementary table 2). Further, it is in weak LD (r²=0.20) with SNP rs12413409 
which has been associated with CAD [12, 33, 36]. But conversely, the latter was only weakly associated 
with PS (p=0.01).  
 
Suggestive plaque score loci identified in the Meta-analysis 
A total of five SNPs showed suggestive association (p<1x10-6) with PS but failed genome-wide 
significance. While two of them correspond to the 9p21 locus and one to 10q24, two additional new 
loci were found:  At chromosome 6q13, the lead SNP rs141249844 is located in the intron of KCNQ5 
and at chromosome 3p24 the lead SNP rs1349287 is located in close proximity to KCNH8. Statistics of 
all loci are summarized in table 2. Interestingly, both genes belong to the calcium channel family. 
 
Verification of top and suggestive SNPs with PS8 
We verified our results with an alternative plaque endpoint, namely PS8. The 9p21 locus remained 
genome-wide significant for PS8 (beta=0.193, p=7.34x10-10). The second hit on 10q24 reached 
suggestive evidence for PS8 (beta=-0.211, p=2.63x10-7). For the suggestive loci at 6q13 and 3p24 no 
suggestive significance was found for the phenotypic alternatives (p=5.35x10-5 and p=3.08x10-4, 
respectively, see also supplementary table 4). Interestingly, higher absolute betas were observed for 
PS8 which however did not resulted in better p values due to the smaller sample size available for PS8. 
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Replication of SNPs associated with plaque prevalence 
A recent meta-GWAS for carotis plaque prevalence (Bis et al. [9]) reported two SNPs  with genome-
wide significance and  three SNPs with suggestive p values. We tested, whether these 5 SNPs were also 
associated with carotid plaque score in our study.  
We found evidence for replication in the LIFE studies (nominal significance and same direction of 
effect) for four of the five SNPs, including the two SNPs with genome-wide significance in Bis et al. [9] 
(table 3 and supplementary table 4 and 5). Only SNP rs17045031 / LRIG1 at chromosome 3p14 failed 
replication. The same results were observed if analyzing plaque prevalence instead of PS (not shown).  
 
Analysis of known CAD loci for association with plaque score 
To investigate if the development of atherosclerotic plaques in the carotid and coronary arteries may 
share a common genetic background, we analyzed whether the 58 lead SNPs at known CAD-loci were 
also associated with PS (see table 3 and supplementary table 4 and 5). CAD association statistics were 
retrieved from Nikpay et al. [2], the most recent meta-GWAS on CAD.  
The CAD lead SNP at the chromosome 9p21 locus, rs2891168, also reached genome-wide significance 
with PS (p=2.31x10-8). This SNP is in high LD (r²=0.75) with the PS lead SNP rs9644862 of our study. In 
addition, seven other CAD lead SNPs reached nominal significance for PS and of those, five SNPs 
showed concordant direction of effects (table 3). Thus, concordant SNPs with nominal significance are 
enriched in this analysis (OR=4.6, p=3.2x10-3).  
Additionally, the literature OR of the CAD SNPs are correlated with the beta estimates (r=0.4, p=0.0017, 
after transforming the OR as suggested by Chinn [37], see also supplementary figure 1). However, the 
beta estimates for PS were on average smaller than those for CAD (t-test of difference, after recoding 
for effect allele, p=1.5x10-7). Restricted to the eight nominal significant SNPs, correlation increased 
(r=0.7, p=0.049), and the difference became insignificant (p=0.68). Using PS8 instead did not improve 
the results.   
We next included sets of proxy SNPs that are in high LD (r²>0.5) with the lead SNP of a CAD locus in our 
analysis. Of note, this included only 57 SNPs, as two CAD SNPs were tagged by the same proxy SNP. 
The number of CAD loci that were also significantly associated with PS (p<0.05) increased to 16, 
suggesting that these CAD loci might also be associated with carotid plaque. To verify this result, we 
performed a permutation test with 10,000 randomly combined sets of genotypes and phenotypes. 
Assuming the data to be Poisson distributed, the empirical p value is 1.03x10-8, which indicates a strong 
enrichment. We also considered the combined effect of all CAD SNPs by calculating a GRS. The GRS 
showed a strong association with PS (beta=0.264, p=1.99x10-6).  
 
Analysis of known cIMT, IS, and LAS loci for association with plaque score 
For four SNPs, association with cIMT [9] was reported. One of them showed nominal significance with 
PS, and the direction of effects are the same. The locus of this SNP is APOC1, which is also reported to 
be a CAD and plaque prevalence locus (with suggestive evidence) [2, 9].  
We found no significant association with the eight SNPs of the most recently published stroke GWAS 
[13]. Dichgans et al. [12] reported 17 SNPs in association with IS or LAS. Three of them showed nominal 
significance with our PS trait, namely rs1333047 at 9p21 (reported for LAS), rs7937106 at 11q22 
(reported for LAS), and rs4792143 at 17p12 (reported for IS). For both LAS SNPs the effect with PS had 
the same direction as reported. However, the SNP reported for IS has opposite direction of effect in 
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our data. Using best proxy SNPs in high LD (r²>0.5) there were six loci significantly associated with PS 
(p<0.05). Permutation test was performed and resulted in an empirical p-value of 2.44x10-4, indicating 
a non-random overlap of stroke loci and loci associated with carotid plaque score.   
In addition, we calculated the genetic risk score for stroke using the published ORs of Dichgans et al. 
[12] and tested the association between this GRS and PS, PS8 and plaque burden at each of the four 
anatomical regions investigated (see methods and supplementary table 6). There was no significant 
association between PS and GRS using all 17 stroke SNPs (beta=0.0658, p=0.20). Restricting the GRS 
on the eleven LAS SNPs, the association becomes significant (beta=0.114, p=0.039). We repeated the 
analysis with PS8, which resulted in significant association for all 17 SNPs (beta=0.225, p=6.8x10-3) as 
well as LAS SNPs only (beta=0.296, p=9.4x10-4). Interestingly, this association is mainly triggered by 
plaque in ICA.  
 
Comparison of LIFE-Heart and LIFE-Adult 
Prevalence of carotid plaque is higher in LIFE-Heart. Therefore, we compared the risk allele frequencies 
(RAF) of our genome-wide significant and suggestive PS hits between LIFE-Heart and LIFE-Adult. The 
same was done for the RAF of the 58 CAD SNPs and the corresponding GRS. Additionally, we compared 
CAD cases and controls (noCAD) of LIFE-Heart with respect to these frequencies. Frequencies are 
shown in supplementary table 7.   
For the PS hits, three of them had higher RAF in LIFE-Heart compared to LIFE-Adult (see also table 2). 
This also applies for the comparison of CAD and noCAD.  
For the 58 CAD SNPs we found no enrichment of risk variants in LIFE-Heart, as only 35 SNPs had higher 
RAF (binomial test, p=0.15). In contrast, comparing CAD and noCAD in LIFE-Heart we observed 39 SNPs 
with higher RAF in cases (binomial test, p=0.012). Results are displayed at supplementary figure 2.  
Similarly, we compared the GRS between our cohorts and between cases and controls of LIFE-Heart. 
As expected, subjects of LIFE-Adult have smaller risk scores than those of LIFE-Heart (t test, p=0.005). 
Controls of LIFE-Heart have smaller GRS than cases (t test, p=0.001). Of note, scores in LIFE-Adult and 




Carotid artery plaque was proposed as a marker to support prediction of prevalent and incident 
coronary events [6–8]. However, assessing plaque status in sufficiently large cohorts is demanding and 
only one meta-GWAS was published for this trait so far [9]. Moreover, there is no generally accepted 
gold standard of carotid plaque assessment, resulting in large heterogeneity of the trait between 
studies. Here, we performed a genetic meta-analysis of two large epidemiologic studies using the same 
operating procedures of plaque assessment, thereby guaranteeing a high degree of comparability and 
high intra- and inter-rater reliability as shown by our feasibility study. We also propose to consider the 
number of affected segments as a more refined trait. We have previously shown [8] that a plaque score 
considering the number of affected segments is a better predictor for obstructive CAD than plaque 
prevalence alone [9]. For our analyses, we relied on a plaque score of the segments CCA and bulb. A 
score including also ICA and ECA was also considered. Although effect sizes appeared to be stronger 
compared to PS, the higher percentage of missingness resulted in inferior power. Nevertheless, our 
study is the first GWAS exploiting plaque score as primary phenotype and resulted in the identification 
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of two loci with genome-wide significance not yet identified with plaque prevalence in genome-wide 
studies.  
The strongest association was observed for SNPs at the 9p21 locus, the most widely replicated locus 
of CAD. Our lead SNP is in high LD with the lead SNP of this locus. The underlying patho-mechanism of 
this locus is subject of intense research and evidence was collected that the non-coding RNAs of 
CDKN2B-AS1 expressed at this locus play a key role [38–40]. The locus is known to be associated with 
several other vascular phenotypes and cardiac events [41, 42].   
The situation for the second strongest locus at chromosome 10 is less obvious. Our top-hit is in an 
intron of SFXN2 and the expression of this gene is strongly controlled by the SNP in several tissues. 
Thus, SFXN2 is the most plausible candidate here.  However, our lead SNP is in low LD with the CAD 
lead SNP (rs12413409) [33]. While the latter shows only marginal association with PS (p=0.01), proxy 
SNPs considered by Nikpay et al. [2] (rs11191416) and us (rs284841) showed some association 
(p=5.17x10-3 and p=1.71x10-4, for rs11191416 and rs284841, respectively). The SNP rs284841 is an 
intron modifier in WBP1L. The same applies for rs9663711 showing suggestive significance in our data. 
Therefore, WBP1L is another plausible candidate gene for this locus.  
Both top-SNPs of our genome-wide significant loci are not described in the study of Bis et al. [9] 
Conversely, we aimed at replicating their loci in our data. It turned out that both genome-wide 
significant SNPs reported in Bis et al. showed at least nominal significance with the same direction of 
effect in our data. We further found supportive evidence, i.e. same direction of effect, for the other 
three SNPs reported as suggestive. Two of them showed nominal significance. This analysis shows that 
further studies and meta-analyses are required to underpin associations with carotid plaque 
phenotypes.   
Another interesting question is to which extend there is a common genetic origin of different 
atherosclerotic manifestations. Although the correlation of carotid plaque and cardiovascular lesion is 
well established [6–8], it is not clear how this translates into common genetic patho-mechanisms. 
Therefore, we present association statistics of reported top-SNPs of CAD loci with our phenotype, 
which takes the number of plaques into account. Although only one of the SNPs showed genome-wide 
significance in our data, we observed an enrichment of concordant effects with at least nominal 
significance. Effect sizes of CAD and PS are positively correlated. This strongly supports our hypotheses 
of common genetic mechanisms underlying the development of atherosclerosis in carotid and 
coronary vessels. In line with this, the strongest CAD locus 9p21 also showed strongest association with 
our plaque score. The GRS of CAD loci was also associated with PS.   
In analogy to the analysis of CAD loci, we investigated the association of cIMT and stroke loci with our 
phenotype. Regarding cIMT, one of the four reported loci was also associated with PS (APOC1).  
Regarding stroke, six of the 17 loci were associated which was significantly more than expected by 
random. Interestingly, the genetic risk score of stroke variants showed stronger association with PS8 
than PS which was mostly triggered by a strong association of LAS loci with ICA. This is in well 
agreement of the pathophysiology of LAS, i.e. plaques in ICA are required for the definition of LAS [14].  
In conclusion, we propose carotid plaque score as a valuable trait of genetic association analysis. By 
performing the first GWAS of this phenotype we identified two loci of genetic association. While the 
9p21 locus is robustly associated with carotid artery plaque score, our hit at chromosome 10 requires 
further replication in independent cohorts as well as identification of the causal gene. Using our plaque 
score, we could replicate four hits associated with carotid plaque prevalence. Comparisons of plaque 
score and CAD associations strongly suggest that there is a larger overlap of genetic causes of the two 
atherosclerotic manifestations. Likewise, we observed an overlap with genetic loci associated with 
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stroke. This overlap becomes stronger for LAS loci analyzed for genetic associations with plaque scores 
comprising ICA.  Larger studies and meta-analyses are required to confine this overlap and possible 
differences in genetic patho-mechanisms.  
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Figures and Tables 
  
Figure 1: QQ-Plot and Manhattan-Plot. (A) QQ-Plot of p values in our meta-analysis. SNPs with info 
score less than 0.8 are plotted as triangles, and those with MAF less than 0.05 are colored red. 
There is no strong inflation (λ = 1.0041). (B) Distribution of log transformed p values in our 
meta-analysis with trait PS. The bold line marks genome-wide significance (p=5x10-8). Two loci 
reach genome-wide significance, one at chromosome 9 (CDKN2B-AS1), and the other one at 






Figure 2: Regional Association Plot. Regional association plots of the two genome-wide significant loci 
at chromosome 9 (A) and 10 (B). The lead SNP of each locus is colored blue (rs9644862 and 
rs2902548 in A and B respectively). All other SNPs are colored according to their linkage 
disequilibrium to the lead SNP. Additional suggestive SNPs (p<1x10-6 and pairwise r²<0.5) are 
encircled in black. 
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Table 1: Patient and participants’ characteristics of LIFE-Heart and LIFE-Adult cohort. All parameters 
are restricted to patients/participants genotyped for the autosomes and with valid PS. For the 
continuous parameters, the unit is in parenthesis and the arithmetic mean and standard deviation is 
given. All categorical parameters were tested with a chi-squared test, continuous parameters were 
tested with a Mann-Whitney U test. Plaque Score was tested with proportional odds regression. All 
parameters except for age show significant differences between the studies. CAD status was not 
compared due to different definitions (LIFE-Heart: coronary angiography, LIFE-Adult: self-reported).  
 
Parameter LIFE-Heart LIFE-Adult p value 
Women / Men (with Chr X) 1111 / 2041 
(1110 / 2039) 
2182 / 1855 
(2179 / 1852) 
 < 0.001 
Age (years) 61.7 ± 10.7 62.1 ± 11.3 ns 
BMI (kg/m²) 29.7 ± 5.0 27.2 ± 4.3  < 0.001 
Diabetes; known, in therapy or acute 963 422  < 0.001 
Smokers; former /current 1330/659 1154/672  < 0.001 
SBP/DBP (mmHg) 139/84 131/76  < 0.001 
Hypertension; known, in therapy or acute 2839 2290  < 0.001 
Lipid Therapy 1192 649  < 0.001 
Cholesterol (mmol/l) 5.44 ± 1.21 5.71 ± 1.07  < 0.001 
HDLC (mmol/l) 1.34 ± 0.41 1.66 ± 0.47  < 0.001 
LDLC (mmol/l) 3.33 ± 1.04 3.55 ± 0.95  < 0.001 
CAD 1259 271  
Plaque Score (PS) 0 1155 1820  < 0.001 
1 549 956 
2 756 902 
3 372 245 
4 320 114 
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Table 2: Genome-wide significant and suggestive SNPs. SNPs associated with carotid plaque at genome-wide significant levels and at suggestive levels (p<1x10-
6) are shown. Beta estimates and p values of LIFE-Heart and LIFE-Adult were obtained by linear regression analysis of plaque score adjusting for age and sex. 
SNP Infos Combined – fixed effect model LIFE-Heart LIFE-Adult 
















G/T 0.131 0.019 8.73x10-12 2.341 0.453 3.36x10-7 0.174 0.425 1.87x10-6 0.111 
10q24 rs2902548 
SFXN2 (0 kb) / 
WBP1L (16 kb) 
rs9663711 T/C -0.141 0.025 1.97x10-8 1.681 0.184 3.94x10-2 -0.093 0.183 7.80x10-8 -0.163 
6q13 rs141249844 KCNQ5 (0 kb) -  T/C 0.475 0.095 5.79x10-7 0.431 0.022 3.21x10-4 0.554 0.020 4.25x10-4 0.426 
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Table 3: Results of previously reported SNPs in our study. SNPs of Bis et al.[9] (trait plaque prevalence) and Nikpay et al.[2] (trait CAD) reaching at least nominal 
significance in our study (trait PS). Tag-SNP denotes the best SNP (minimal p value) in LD with the reported top-SNP (r²>0.5). Some SNPs were reversely coded in 
the reference (marked with a). For better comparison, we transformed their OR into its inverse. After transformation, six CAD-SNPs showed a different direction 
of effect (marked with b) when compared to our PS trait. For further information, see supplementary table 4 and 5.  
 
 
SNP Infos literature 
Association of 
Lead SNP with PS 
Best associated tag SNP 
 








β ± SE /  
OR (95% CI) 









3p14 rs17045031 LRIG1 A/G 
0.032 
0.036 
-0.297 ± 0.059 4.00x10-7 9.95x10-2 -0.082 rs76405716 5.63x10-2 -0.093 
4q31 rs1878406 EDNRA T/C 
0.141 
0.141 
0.199 ± 0.029 6.90x10-12 1.86x10-2 0.061 rs6820938 6.37x10-4 0.081 
7q22 rs17398575 PIK3CG A/G 
0.250 
0.243 
0.162 ± 0.023 2.30x10-12 4.40x10-2 0.043 rs12705390 3.63x10-3 0.065 
19p13 rs6511720 LDLR T/G 
0.086 
0.099 
-0.178 ± 0.033 1.00x10-7 4.66x10-2 -0.063 rs17242381 8.51x10-3 -0.082 






















5.00x10-14 2.47x10-1 -0.039 rs72664358 1.49x10-2 -0.060 























3.62x10-10 3.45x10-1 0.017 rs6747828 1.29x10-2 0.050 














1.85x10-8 8.88x10-2 0.067 rs10455872 4.66x10-2 0.078 
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9.60x10-1 2.23x10-1 0.049 rs10455872 4.66x10-2 0.078 





2.61x10-6 1.37x10-3 -0.059 rs2980868 7.18x10-4 -0.062 





2.29x10-98 2.31x10-8 0.101 rs9644862 8.73x10-12 0.131 















4.65x10-9 5.17x10-3 -0.081 rs284841 1.71x10-4 0.105 





1.03x10-9 2.20x10-2 0.059 rs4842666 4.57x10-3 0.076 





7.13x10-5 1.43x10-1 -0.030 rs9515199 1.75x10-2 0.045 














1.84x10-5 4.21x10-2 -0.038 rs58251514  1.72x10-2 -0.046 














7.07x10-11 9.27x10-3 0.069 rs429358 7.63x10-4 0.104 
a – SNPs were reversely coded in the reference 
b – SNPs with a different direction of effect 
